Share on LinkedInShare on LinkedIn

ARTICLE · 20 OCTOBER 2021

Another Example Of Invalid Claims For Lack Of Written Description And Enablement

In its recent decision, the PTAB ("the Board") determined that all challenged claims of U.S. Patent No. 10,301,638 B2 were unpatentable under 35 U.S.C. § 328(a) for lack of written description and lack of enablement.

United StatesIntellectual Property

In its recent decision, the PTAB (“the Board”) determined that all challenged claims of U.S. Patent No. 10,301,638 B2 were unpatentable under 35 U.S.C. § 328(a) for lack of written description and lack of enablement.

Commonwealth Scientific and Industrial Research Organization (“Petitioner”) filed a Petition to institute a post-grant review of claims 1-23 of the '638 patent owned by BASF Plant Science GMBH (“Patent Owner”). The patent, issued on May 28, 2019, relates to a process for the production of eicosapentaenoic acid (“EPA”), docosapentaenoic acid (“DPA”), and/or docosahexaenoic acid (“DHA”) in transgenic plants, and to “oils, lipids, and/or fatty acids which have been produced by the process.” The patent describes that the yield of long-chain polyunsaturated fatty acids “can be increased by expressing an optimized Δ5-elongase sequence in transgenic plants” and that the fatty acids produced by the process are present with a content of, in each case, at least

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from